Message from the editors to our reviewers

Robert A. Gross; David S. Knopman; Gregory D. Cascino; John R. Corboy; Mitchell S.V. Elkind; Andrew G. Engel; Jonathan W. Mink; Richard M. Ransohoff; Ryan J. Uitti; Bradford B. Worrall

doi:10.1212/WNL.0b013e31827ec551

Message from the editors to our reviewers

Robert A. Gross, David S. Knopman, Gregory D. Cascino, John R. Corboy, Mitchell S.V. Elkind, Andrew G. Engel, Jonathan W. Mink, Richard M. Ransohoff, Ryan J. Uitti, Bradford B. Worrall

Research output: Contribution to journal › Review article › peer-review

Original language	English (US)
Pages (from-to)	5-12
Number of pages	8
Journal	Neurology
Volume	80
Issue number	1
DOIs	https://doi.org/10.1212/WNL.0b013e31827ec551
State	Published - Jan 1 2013

ASJC Scopus subject areas

Clinical Neurology

Access to Document

10.1212/WNL.0b013e31827ec551

Cite this

@article{07ec78ff8bb74c9f96aadbdb66edf32d,

title = "Message from the editors to our reviewers",

author = "Gross, {Robert A.} and Knopman, {David S.} and Cascino, {Gregory D.} and Corboy, {John R.} and Elkind, {Mitchell S.V.} and Engel, {Andrew G.} and Mink, {Jonathan W.} and Ransohoff, {Richard M.} and Uitti, {Ryan J.} and Worrall, {Bradford B.}",

note = "Funding Information: Robert A. Gross, MD, PhD, FAAN, has received research funding from the Department of the Army and UCBPharma. He is supported for educational endeavors from the University of Rochester Medical Center's Clinical and Translational Science Award from the NIH. Dr. Gross has conducted clinical trials over the past 5 years funded by GlaxoSmithKline, UCB, Ortho-McNeil, Pfizer, and Marinus. He has served on the speakers' bureaus for Abbott, UCB, and GlaxoSmithKline and has received consultant fees from GlaxoSmithKline and Harris Interactive. Since his appointment as Editor-in-Chief, Dr. Gross has ceased participation in industry-sponsored clinical trials and speakers' bureaus. He receives an honorarium from the AAN as Editor-in-Chief of Neurology. Funding Information: David S. Knopman, MD, serves on a Data Safety Monitoring Board for Lilly and is an investigator for clinical trials sponsored by Baxter Pharmaceuticals, Elan Pharmaceuticals, and Forest Pharmaceuticals. He participated in 2 single-session consultancies, one with Janssen and another with Merck, in which the honoraria were turned over to his institution. Dr. Knopman is supported by grants U01 AG 06786 (Mayo Alzheimer's Disease Patient Registry, RC Petersen PI), P50 AG 16574 (Mayo Alzheimer's Disease Research Center, RC Petersen PI), U01 AG 10483-7 (Alzheimer's Disease Cooperative Study, P Aisen PI), R01 AG11378-16 (Identifying Mechanisms of Dementia: Role for MRI in the Era of Molecular Imaging, C Jack PI), R01 HL96917 (The ARIC Neurocognitive Study, Thomas Mosley PI), R01 AG032306, Frontotemporal Lobar Degeneration Neuroimaging Initiative, H Rosen PI), R01 AG037551 (Stroke and Cognitive Impairment in Aging Chronic Kidney Disease Patients, Anne Murray PI) . He is Deputy Editor of Neurology for which he receives compensation from the AAN. Funding Information: Gregory D. Cascino, MD, is co-investigator of a study sponsored by NeuroPace, Inc., Sunnyvale, CA (RNS in Partial Epilepsy), and is supported by grant NS53998-03 (The Epilepsy Phenome/Genome Project) . He receives an honorarium from the AAN as an Associate Editor of Neurology. Funding Information: John R. Corboy, MD, conducts research supported by the NIH, the National MS Society, Juvenile Diabetes Research Foundation, Immune Tolerance Network (NIAID), Genentech, Novartis, Eli Lilly, Bio-MS, Orasi, and Celgene Therapeutics and has been a consultant for Celgene Therapeutics and Teva Neurosciences. Dr. Corboy has received honoraria for speaking from ProCE and the Rocky Mountain MS Center. He is a Section Editor for Neurology Today and receives an honorarium from the AAN as an Associate Editor of Neurology and Editor of Neurology: Clinical Practice. Funding Information: Mitchell S. V. Elkind, MD, MS, FAAN, serves as a consultant to Bristol-Myers Squibb and Tethys Bioscience, Inc.; serves on an event adjudication committee for Jarvik Heart; serves on speakers' bureaus for Boehringer–Ingelheim, Inc., Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership, and Genentech; receives research support from diaDexus, Inc., Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership, and the NIH/NINDS [R01 NS050724 (PI), NS048134 (PI), P50 NS049060 (Project PI), R37 NS029993 (Co-PI), R01 NS55809 (Co-I), and R01 NS062820 (Co-I)]; and has given expert testimony on behalf of Novartis (Zelnorm{\textregistered} and stroke litigation) and GlaxoSmithKline (Avandia{\textregistered} and stroke litigation). Dr. Elkind serves as Resident & Fellow Section Editor for Neurology, for which he receives compensation from the AAN. Funding Information: Andrew G. Engel, MD, FAAN, receives research funding from the NIH and from the Muscular Dystrophy Association. As an Associate Editor of Neurology, he receives an honorarium from the AAN. Funding Information: Jonathan W. Mink, MD, PhD, has received research support from NIH/NINDS and the CDC. Dr. Mink serves on the Board of Scientific Counselors, NINDS. Dr. Mink has received travel funding from the Tourette Syndrome Association. He is an Editorial Board Member of Continuum, Pediatric Neurology, and the Journal of Child Neurology. Dr. Mink has received honoraria from the Tourette Syndrome Association and receives an honorarium as an Associate Editor of Neurology. Funding Information: Richard M. Ransohoff, MD, conducts research supported by the NIH, the National MS Society, Williams Family Foundation for MS Research, Chemocentryx, and Biogen-Idec. Dr. Ransohoff has received fees for pre-clinical consulting or honoraria for academic presentations from Novartis, Biogen-Idec, and Pfizer. He serves on Scientific Advisory, Medical Advisory, or Safety Monitoring Boards for Chemocentryx, Vertex, Merck, Glaxo Smith Kline, and Johnson & Johnson. As an Associate Editor of Neurology, he receives an honorarium from the AAN. Funding Information: Ryan J. Uitti, MD, FAAN, has received research funding from the NIH, Noscira, Inc., and Advanced Neuromodulation Systems, Inc. His institution has received annual royalties from the licensing of the technology related to PARK8/LRRK2 greater than the federal threshold for significant financial interest; Dr. Uitti has not received any royalties. Dr. Uitti receives an honorarium as an Associate Editor of Neurology. Funding Information: Bradford B. Worrall, MD, MSc, has received research funding from NIH (6 grants). He serves as an outcomes adjudicator for the NHLBI for AREDS2 and as an ad hoc reviewer for the NIH and Veterans Administration study sections. Dr. Worrall received several honoraria for serving as faculty and/or director for courses at the AAN annual meetings and an honorarium for speaking for the Operation Stroke program (AHA/ASA funded) at Fairfax Inova Hospital. Dr. Worrall is on the Editorial Boards of Neurology and Seminars in Neurology. Dr. Worrall received nominal royalties for serving as a Chapter Author for Merritt's Neurology and receives an honorarium as an Associate Editor of Neurology.",

year = "2013",

month = jan,

day = "1",

doi = "10.1212/WNL.0b013e31827ec551",

language = "English (US)",

volume = "80",

pages = "5--12",

journal = "Neurology",

issn = "0028-3878",

publisher = "Lippincott Williams and Wilkins",

number = "1",

}

TY - JOUR

T1 - Message from the editors to our reviewers

AU - Gross, Robert A.

AU - Knopman, David S.

AU - Cascino, Gregory D.

AU - Corboy, John R.

AU - Elkind, Mitchell S.V.

AU - Engel, Andrew G.

AU - Mink, Jonathan W.

AU - Ransohoff, Richard M.

AU - Uitti, Ryan J.

AU - Worrall, Bradford B.

N1 - Funding Information: Robert A. Gross, MD, PhD, FAAN, has received research funding from the Department of the Army and UCBPharma. He is supported for educational endeavors from the University of Rochester Medical Center's Clinical and Translational Science Award from the NIH. Dr. Gross has conducted clinical trials over the past 5 years funded by GlaxoSmithKline, UCB, Ortho-McNeil, Pfizer, and Marinus. He has served on the speakers' bureaus for Abbott, UCB, and GlaxoSmithKline and has received consultant fees from GlaxoSmithKline and Harris Interactive. Since his appointment as Editor-in-Chief, Dr. Gross has ceased participation in industry-sponsored clinical trials and speakers' bureaus. He receives an honorarium from the AAN as Editor-in-Chief of Neurology. Funding Information: David S. Knopman, MD, serves on a Data Safety Monitoring Board for Lilly and is an investigator for clinical trials sponsored by Baxter Pharmaceuticals, Elan Pharmaceuticals, and Forest Pharmaceuticals. He participated in 2 single-session consultancies, one with Janssen and another with Merck, in which the honoraria were turned over to his institution. Dr. Knopman is supported by grants U01 AG 06786 (Mayo Alzheimer's Disease Patient Registry, RC Petersen PI), P50 AG 16574 (Mayo Alzheimer's Disease Research Center, RC Petersen PI), U01 AG 10483-7 (Alzheimer's Disease Cooperative Study, P Aisen PI), R01 AG11378-16 (Identifying Mechanisms of Dementia: Role for MRI in the Era of Molecular Imaging, C Jack PI), R01 HL96917 (The ARIC Neurocognitive Study, Thomas Mosley PI), R01 AG032306, Frontotemporal Lobar Degeneration Neuroimaging Initiative, H Rosen PI), R01 AG037551 (Stroke and Cognitive Impairment in Aging Chronic Kidney Disease Patients, Anne Murray PI) . He is Deputy Editor of Neurology for which he receives compensation from the AAN. Funding Information: Gregory D. Cascino, MD, is co-investigator of a study sponsored by NeuroPace, Inc., Sunnyvale, CA (RNS in Partial Epilepsy), and is supported by grant NS53998-03 (The Epilepsy Phenome/Genome Project) . He receives an honorarium from the AAN as an Associate Editor of Neurology. Funding Information: John R. Corboy, MD, conducts research supported by the NIH, the National MS Society, Juvenile Diabetes Research Foundation, Immune Tolerance Network (NIAID), Genentech, Novartis, Eli Lilly, Bio-MS, Orasi, and Celgene Therapeutics and has been a consultant for Celgene Therapeutics and Teva Neurosciences. Dr. Corboy has received honoraria for speaking from ProCE and the Rocky Mountain MS Center. He is a Section Editor for Neurology Today and receives an honorarium from the AAN as an Associate Editor of Neurology and Editor of Neurology: Clinical Practice. Funding Information: Mitchell S. V. Elkind, MD, MS, FAAN, serves as a consultant to Bristol-Myers Squibb and Tethys Bioscience, Inc.; serves on an event adjudication committee for Jarvik Heart; serves on speakers' bureaus for Boehringer–Ingelheim, Inc., Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership, and Genentech; receives research support from diaDexus, Inc., Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership, and the NIH/NINDS [R01 NS050724 (PI), NS048134 (PI), P50 NS049060 (Project PI), R37 NS029993 (Co-PI), R01 NS55809 (Co-I), and R01 NS062820 (Co-I)]; and has given expert testimony on behalf of Novartis (Zelnorm® and stroke litigation) and GlaxoSmithKline (Avandia® and stroke litigation). Dr. Elkind serves as Resident & Fellow Section Editor for Neurology, for which he receives compensation from the AAN. Funding Information: Andrew G. Engel, MD, FAAN, receives research funding from the NIH and from the Muscular Dystrophy Association. As an Associate Editor of Neurology, he receives an honorarium from the AAN. Funding Information: Jonathan W. Mink, MD, PhD, has received research support from NIH/NINDS and the CDC. Dr. Mink serves on the Board of Scientific Counselors, NINDS. Dr. Mink has received travel funding from the Tourette Syndrome Association. He is an Editorial Board Member of Continuum, Pediatric Neurology, and the Journal of Child Neurology. Dr. Mink has received honoraria from the Tourette Syndrome Association and receives an honorarium as an Associate Editor of Neurology. Funding Information: Richard M. Ransohoff, MD, conducts research supported by the NIH, the National MS Society, Williams Family Foundation for MS Research, Chemocentryx, and Biogen-Idec. Dr. Ransohoff has received fees for pre-clinical consulting or honoraria for academic presentations from Novartis, Biogen-Idec, and Pfizer. He serves on Scientific Advisory, Medical Advisory, or Safety Monitoring Boards for Chemocentryx, Vertex, Merck, Glaxo Smith Kline, and Johnson & Johnson. As an Associate Editor of Neurology, he receives an honorarium from the AAN. Funding Information: Ryan J. Uitti, MD, FAAN, has received research funding from the NIH, Noscira, Inc., and Advanced Neuromodulation Systems, Inc. His institution has received annual royalties from the licensing of the technology related to PARK8/LRRK2 greater than the federal threshold for significant financial interest; Dr. Uitti has not received any royalties. Dr. Uitti receives an honorarium as an Associate Editor of Neurology. Funding Information: Bradford B. Worrall, MD, MSc, has received research funding from NIH (6 grants). He serves as an outcomes adjudicator for the NHLBI for AREDS2 and as an ad hoc reviewer for the NIH and Veterans Administration study sections. Dr. Worrall received several honoraria for serving as faculty and/or director for courses at the AAN annual meetings and an honorarium for speaking for the Operation Stroke program (AHA/ASA funded) at Fairfax Inova Hospital. Dr. Worrall is on the Editorial Boards of Neurology and Seminars in Neurology. Dr. Worrall received nominal royalties for serving as a Chapter Author for Merritt's Neurology and receives an honorarium as an Associate Editor of Neurology.

PY - 2013/1/1

Y1 - 2013/1/1

UR - http://www.scopus.com/inward/record.url?scp=84873653200&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873653200&partnerID=8YFLogxK

U2 - 10.1212/WNL.0b013e31827ec551

DO - 10.1212/WNL.0b013e31827ec551

M3 - Review article

AN - SCOPUS:84873653200

SN - 0028-3878

VL - 80

SP - 5

EP - 12

JO - Neurology

JF - Neurology

IS - 1

ER -

Message from the editors to our reviewers

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this